Orthopedic implants market seen reaching $103B by 2035

Market Research Future projects the global orthopedic implants market will rise from $66.65 billion in 2026 to $103.05 billion by 2035, supported by aging populations, osteoarthritis growth, robotics and outpatient surgery. The forecast points to faster adoption in Asia-Pacific, expanding ambulatory care, and more AI-driven planning across joint, spine and trauma procedures.

Why it matters: - The global orthopedic implants market is moving from a $63.50 billion base in 2025 to a projected $103.05 billion by 2035. - Demand is being driven by older populations, higher osteoarthritis prevalence, and more procedures shifting to outpatient settings. - The growth outlook also reflects wider use of robotics, 3-D printing and AI-enabled surgical planning.

What happened: - Market Research Future projects the orthopedic implants market will grow from $66.65 billion in 2026 to $103.05 billion by 2035. - The forecast implies a 4.96% compound annual growth rate from 2026 to 2035. - Aging demographics, osteoarthritis burden and broader access to joint replacement are the main demand drivers. - The report includes a free sample, a customization request and the full market report.

The details: - The World Health Organization estimates the global population aged 60 and older will double to 2.1 billion by 2050. - The Lancet’s 2023 Global Burden of Disease update says more than 500 million people already have osteoarthritis worldwide. - U.S. Medicare policy changes moved total knee arthroplasty to outpatient status in 2018 and total hip arthroplasty in 2020. - China’s volume-based procurement program cut domestic implant prices by 50% to 80% and tripled procedure volumes in covered provinces between 2021 and 2024. - India’s Ayushman Bharat policy covers joint replacement for 500 million beneficiaries and funded more than 120,000 arthroplasties in fiscal 2024, up 45% year over year. - In the U.S., cementless total knee arthroplasty increased from 8% to 22% of primary procedures between 2018 and 2024. - Robotic platforms were used in about 12% of U.S. total knee arthroplasties in 2025, up from under 3% in 2018. - Stryker’s Mako platform had more than 2,500 cumulative global system placements by mid-2025. - The FDA cleared more than 180 3-D printed orthopedic devices between 2020 and 2025. - ASCs now perform an estimated 18% of primary hip and knee replacements in the U.S. and are expected to exceed 35% by 2030. - Registry data from more than 45,000 ASC-based arthroplasties showed 90-day readmission rates of 2.1% versus 2.4% for inpatient settings.

Between the lines: - The market is shifting from one-time implant sales toward integrated procedural platforms that combine hardware, software and post-op workflow. - Robotic systems can deepen manufacturer lock-in because hospitals that buy the capital equipment often stay with the same implant portfolio for years. - Outpatient migration opens demand beyond large hospitals and expands access to community ASCs and specialty clinics. - Pricing pressure is rising in some markets, even as procedure volume grows, which could favor scale players with broad distribution and bundled offerings.

What's next: - By 2030, analysts expect robotic-assisted and navigation systems to take a much larger share of procedures. - AI-enabled surgical planning is expected to become a standard procurement requirement for hospitals. - Manufacturers are likely to push more ASC-specific implant kits, disposable trays and logistics bundles. - Asia-Pacific is expected to remain the fastest-growing region through 2035. - North America should keep leading revenue, while Europe and Asia-Pacific drive the biggest volume shifts.

The bottom line: - Orthopedic implants are becoming a volume-and-technology story, not just a demographic one, with growth tied to robotics, outpatient care and payor-backed access expansion.